Cancer Tumor Profiling Market worth $19.87 billion by 2031
The report "Cancer Tumor Profiling Market by Product & Service Offering (Instruments/Systems, Assays/Kits, Services), Technology (NGS, PCR, IHC, ISH/FISH), Sample Type (Tissue, Blood, Bone Marrow), Application, Cancer Type, End User & Region – Global Forecast to 2031", The cancer tumor profiling market is projected to reach USD 19.87 billion by 2031 from USD 12.02 billion in 2026, at a CAGR of 10.6%. The global cancer tumor profiling market is experiencing strong growth, driven by the rising adoption of precision oncology, increasing use of targeted therapies and immunotherapies, expanding comprehensive genomic profiling, and growing demand for biomarker-guided treatment selection. Wider use of liquid biopsy, stronger pharmaceutical–diagnostic collaborations, and increasing integration of molecular profiling into clinical trials are further supporting market expansion.
Browse 313 market data Tables and 64 Figures spread through 315 Pages and in-depth TOC on "Cancer Tumor Profiling Market by Product & Service Offering (Instruments/Systems, Assays/Kits, Services), Technology (NGS, PCR, IHC, ISH/FISH), Sample Type (Tissue, Blood, Bone Marrow), Application, Cancer Type, End User & Region – Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cancer-tumor-profiling-market-1250.html
Assays, kits, reagents, and consumables accounted for the largest share of the global cancer tumor profiling market, by offering, in 2025.
Based on offering, the cancer tumor profiling market is segmented into instruments & systems; assays, kits, reagents, and consumables; clinical tumor profiling testing services; and biopharmaceutical, clinical-trial, and companion diagnostic services. In 2025, assays, kits, reagents, and consumables accounted for the largest share, supported by recurring demand across NGS, PCR, immunohistochemistry, and in situ hybridization workflows. The segment benefits from repeat utilization of sequencing reagents, antibodies, probes, primers, controls, and other workflow-specific consumables across hospitals, reference laboratories, and pharmaceutical research programs.
Next-generation sequencing accounted for the largest share of the cancer tumor profiling market, by technology, in 2025.
Based on technology, the market is segmented into next-generation sequencing, polymerase chain reaction, immunohistochemistry, in situ hybridization, and other tumor profiling technologies. In 2025, next-generation sequencing held the leading position in value terms due to its ability to evaluate multiple genes and genomic alterations simultaneously, support comprehensive tumor characterization, and identify clinically actionable biomarkers from tissue and blood samples. NGS is expected to register strong growth during the forecast period as broad-panel testing, decentralized sequencing workflows, and companion diagnostic applications continue to expand.
Solid tumors accounted for the largest share of the cancer tumor profiling market, by cancer type, in 2025.
Based on cancer type, the market is segmented into solid tumors and liquid tumors or hematologic malignancies. In 2025, solid tumors accounted for the largest share, driven by high testing volumes across lung, breast, colorectal, prostate, gynecologic, melanoma, brain and central nervous system, head and neck, gastrointestinal, pancreatic, liver, and biliary tract cancers. The increasing use of broad NGS panels, IHC-based biomarkers, and blood-based profiling in advanced solid tumors continues to support the dominance of this segment.
Tissue samples accounted for the largest share of the cancer tumor profiling market, by sample type, in 2025.
Based on sample type, the market is segmented into tissue, blood, and others. Tissue samples accounted for the largest share in 2025, supported by their established role in tumor profiling, IHC/ISH-based biomarker assessment, and pathology-driven treatment decisions. Blood-based testing is expected to grow rapidly due to increasing adoption of liquid biopsy, repeat-testing potential, and usefulness in cases where tissue availability is limited.
Cancer diagnosis, molecular characterization, and prognostic/risk assessment accounted for the largest share of the cancer tumor profiling market, by application, in 2025.
Based on applications, the market is divided into clinical applications and research & drug development applications. Clinical applications include cancer diagnosis, molecular characterization, and prognostic/risk assessment; treatment selection & companion diagnostics; treatment-response and resistance monitoring; and residual disease, post-treatment surveillance, and recurrence detection. In 2025, cancer diagnosis, molecular characterization, and prognostic/risk assessment accounted for the largest share because tumor profiling is increasingly integrated into the initial evaluation, classification, and risk stratification of solid and hematologic cancers. Treatment selection and companion diagnostics are expected to expand strongly as more oncology therapies require biomarker-defined patient selection
Hospitals, cancer centers, and oncology clinics accounted for the largest share of the cancer tumor profiling market, by end user, in 2025.
Based on end user, the market is segmented into hospitals, cancer centers, and oncology clinics; independent & specialty reference laboratories; pharmaceutical & biotechnology companies; contract research organizations & central laboratories; and other end users, including research institutes and academic medical center laboratories. In 2025, hospitals, cancer centers, and oncology clinics accounted for the largest share due to their central role in cancer diagnosis, multidisciplinary treatment planning, tissue pathology, and longitudinal patient management. Independent and specialty reference laboratories also represent a major customer group by providing high-complexity and high-throughput profiling to institutions without comprehensive in-house capabilities
North America accounted for the largest regional share of the global cancer tumor profiling market in 2025.
The cancer tumor profiling market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, North America accounted for the largest share, supported by high oncology testing volumes, broad access to NGS and liquid-biopsy technologies, advanced laboratory infrastructure, favorable reimbursement for selected profiling tests, and the presence of leading diagnostics, sequencing, precision-oncology, and biopharmaceutical companies. Europe remains a significant market due to established molecular pathology networks and growing adoption of biomarker-guided treatment, while Asia Pacific is expected to witness the fastest growth as cancer testing capacity expands, healthcare investment rises, and advanced tumor profiling becomes more accessible across major oncology centers.
Key players in the cancer tumor profiling market include F. Hoffmann-La Roche AG (Switzerland), Illumina, Inc. (US), Guardant Health, Inc. (US), Tempus AI, Inc. (US), Thermo Fisher Scientific Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), NeoGenomics, Inc. (US), Myriad Genetics, Inc. (US), Agilent Technologies, Inc. (US), Quest Diagnostics Incorporated (US), Caris Life Sciences, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), and Abbott (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cancer Tumor Profiling Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
